HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

P M Humpert Selected Research

Type 2 Diabetes Mellitus (MODY)

6/2014Effects of stress reduction on cardiovascular risk factors in type 2 diabetes patients with early kidney disease - results of a randomized controlled trial (HEIDIS).
11/2013Urinary n-acetyl-beta-d-glucosaminidase excretion: an indicator of neuropathy in type 2 diabetes.
4/2012Is diabetes an acquired disorder of reactive glucose metabolites and their intermediates?
7/2009Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes.
4/2009The -174G>C IL-6 gene promoter polymorphism and diabetic microvascular complications.
2/2008Clinical benefit of a short term dietary oatmeal intervention in patients with type 2 diabetes and severe insulin resistance: a pilot study.
12/2007sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes.
9/2007Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease.
9/2007Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.
9/2004Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


P M Humpert Research Topics

Disease

10Type 2 Diabetes Mellitus (MODY)
06/2014 - 09/2004
4Diabetes Complications
11/2013 - 01/2008
3Hyperglycemia
01/2016 - 12/2001
3Diabetic Neuropathies (Diabetic Neuropathy)
11/2013 - 07/2007
3Metabolic Syndrome (Dysmetabolic Syndrome X)
07/2009 - 05/2005
2Insulin Resistance
02/2008 - 09/2007
2Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/2008 - 12/2001
1Thymoma (Thymic Carcinoma)
01/2016
1Peripheral Nervous System Diseases (PNS Diseases)
11/2013
1Albuminuria
11/2013
1Diabetic Nephropathies (Diabetic Nephropathy)
02/2010
1Atherosclerosis
07/2009
1Coronary Artery Disease (Coronary Atherosclerosis)
09/2007
1Inflammation (Inflammations)
09/2007
1Wounds and Injuries (Trauma)
10/2005
1Metabolic Diseases (Metabolic Disease)
05/2005
1Diabetes Mellitus
05/2005
1Cardiovascular Diseases (Cardiovascular Disease)
05/2005
1Chronic Disease (Chronic Diseases)
12/2001

Drug/Important Bio-Agent (IBA)

3Glucose (Dextrose)FDA LinkGeneric
06/2014 - 09/2004
3NF-kappa B (NF-kB)IBA
09/2007 - 12/2001
1LinagliptinIBA
01/2016
1LiraglutideFDA Link
01/2016
1Indicators and Reagents (Reagents)IBA
11/2013
1Acetylglucosaminidase (NAGase)IBA
11/2013
1Glyceraldehyde-3-Phosphate Dehydrogenases (GAPD)IBA
04/2012
1Biomarkers (Surrogate Marker)IBA
02/2010
1Hexosaminidases (Hexosaminidase)IBA
02/2010
1Protein Isoforms (Isoforms)IBA
07/2009
1Atorvastatin (Lipitor)FDA Link
07/2009
1AdiponectinIBA
07/2009
1Interleukin-6 (Interleukin 6)IBA
04/2009
1NucleotidesIBA
04/2009
1CarbohydratesIBA
02/2008
1Proteins (Proteins, Gene)FDA Link
01/2008
1DNA Restriction Enzymes (Restriction Endonuclease)IBA
01/2008
1human esRAGE proteinIBA
12/2007
1CholesterolIBA
09/2007
1Pioglitazone (Actos)FDA Link
09/2007
1Lipase (Acid Lipase)FDA Link
09/2007
1Lipoproteins (Lipoprotein)IBA
09/2007
1LDL CholesterolIBA
09/2007
1Retinol-Binding Proteins (Retinoid Binding Proteins)IBA
09/2007
1Triglycerides (Triacylglycerol)IBA
09/2007
1VLDL CholesterolIBA
09/2007
1NAD (NADH)IBA
07/2007
1Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity)IBA
07/2007
1erucylphosphocholineIBA
05/2005
1AcarboseFDA LinkGeneric
09/2004
1Transcription Factors (Transcription Factor)IBA
09/2004
1Glycoside Hydrolase InhibitorsIBA
09/2004
1LigandsIBA
12/2001
1NF-KappaB Inhibitor alphaIBA
12/2001

Therapy/Procedure

1Therapeutics
07/2009
1Aftercare (After-Treatment)
10/2005